PERLANE approved for sales in the USA

PERLANE approved for sales in the USA

The U.S. Food and Drug Administration (“FDA”) has approved PERLANE for sales in
the USA.

FDA's approval of PERLANE means that Q-Med will receive the final purchase sum
from the agreement 2003 of USD 29.1 million from the American company Medicis,
which holds the rights to sell and market PERLANE in the USA and Canada. Q-Med
is the exclusive manufacturer of the product. Medicis anticipates that it will
be able to begin selling PERLANE in the USA within 30 days.

PERLANE consists of a crystal-clear gel that is injected into the skin for the
filling out of deeper folds and wrinkles and for the treatment of lips. In the
USA the approval only comprises the filling out of folds and wrinkles. The
product is based on Q-Med's patented technology, NASHA, for the production of
stabilized, non-animal hyaluronic acid and has been approved in Europe since the
year 2000.

Medicis is a leading specialty pharmaceutical company in the USA within
dermatology that offers products for, amongst other things, the treatment of
acne, asthma, hyperpigmentation, psoriasis, eczema, skin infections and a large
number of other skin-related conditions. Medicis is listed on NYSE (MRX).






Queries should be addressed to:
Erika Kjellberg Eriksson, Vice President and CFO, Tel: +46 (0)70-974 90 20.

--------------------------------------------------------------------
Q-Med AB is a rapidly growing and profitable biotechnology/medical device
company. The company develops, manufactures, markets and sells primarily medical
implants. The majority of the products are based on the company's patented
technology, NASHA™ for the production of stabilized non-animal hyaluronic acid. 
The product portfolio today contains: RESTYLANE for the filling out of lips and
facial wrinkles and for facial contouring, DUROLANE, for the treatment of
osteoarthritis of the hip and knee joints, DEFLUX for the treatment of
vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children,
ZUIDEX, for the treatment of stress urinary incontinence in women and SOLESTA,
for the treatment of fecal incontinence. Sales are made through the company's
own subsidiaries or distributors in over 70 countries. Q-Med today has just over
600 co-workers, with approximately 400 at the company's head office and
production facility in Uppsala, Sweden. Q-Med AB is listed in the Large Cap
segment of the OMX Nordic Stock Exchange in Stockholm.

NASHA, DUROLANE, SOLESTA, ZUIDEX, IMPLACER, DEFLUX and all product names within
the RESTYLANE family are trademarks that belong to Q-Med AB.
________________________________________________________________
Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Tel: 018-474 90 00, Fax:
018-474 90 01
info@q-med.com, www.q-med.com, Org.nr. 556258-6882

In the US, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med
Scandinavia, Inc.